AEON Biopharma Files 8-K: Reg FD & Financials

Ticker: AEON · Form: 8-K · Filed: Dec 4, 2025 · CIK: 1837607

Sentiment: neutral

Topics: disclosure, financials

TL;DR

AEON Biopharma dropped an 8-K on Dec 4th covering Reg FD and financials. Check it out.

AI Summary

AEON Biopharma, Inc. filed an 8-K on December 4, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Priveterra Acquisition Corp., is incorporated in Delaware and headquartered in Irvine, California.

Why It Matters

This filing provides important updates on AEON Biopharma's regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of information and does not appear to contain any significant new risks or adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for AEON Biopharma, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on December 4, 2025.

What was AEON Biopharma, Inc.'s former name?

AEON Biopharma, Inc.'s former name was Priveterra Acquisition Corp.

Where are AEON Biopharma, Inc.'s principal executive offices located?

AEON Biopharma, Inc.'s principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.

Under which section of the Securities Exchange Act is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-12-04 09:02:14

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 4, 2025, AEON Biopharma, Inc. (the "Company" or "AEON") made available in the investor relations section of its website a presentation (the "Corporate Presentation"), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled "Forward-Looking Statements" in Exhibit 99.1 attached hereto. The information furnished in this Item 7.01 of this Current Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated December 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: December 4, 2025 By: /s/ Robert Bancroft Robert Bancroft Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing